phosphorylcholine has been researched along with Astrocytoma, Grade IV in 27 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A series of polymer-drug conjugates based on 2-methacryloyloxyethyl phosphorylcholine (MPC) was prepared with the glioblastoma drug temozolomide (TMZ) as pendent groups." | 7.88 | Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma. ( Emrick, T; Saha, B; Skinner, M; Ward, SM, 2018) |
| "Recent experimental data showed that the PI3K pathway contributes to resistance to temozolomide (TMZ) in paediatric glioblastoma and that this effect is reversed by combination treatment of TMZ with a PI3K inhibitor." | 7.85 | In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells. ( Agliano, A; Al-Saffar, NMS; Balarajah, G; Clarke, PA; Jackson, LE; Jones, C; Leach, MO; Marshall, LV; Pearson, ADJ; Sidhu, J; Workman, P, 2017) |
| "Hexadecylphosphocholine (HePC) or miltefosine based proapoptotic lipid nanovesicles encapsulating paclitaxel for synergistic anticancer effect of paclitaxel and miltefosine in chemoresistant human glioblastoma multiforme (U-87 MG) overexpressing multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp), were developed in this study." | 7.79 | Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy. ( Banerjee, R; Joshi, N; Shanmugam, T; Thakur, A, 2013) |
| "Perifosine was fixed as a 600 mg load on day 1 followed by 100 mg nightly (single agent MTD) until dose level 7 when the load increased to 900 mg." | 6.94 | Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. ( Abrey, LE; DeAngelis, LM; Gavrilovic, I; Holland, EC; Kaley, TJ; Lacouture, ME; Lassman, AB; Ludwig, E; Mellinghoff, IK; Nolan, C; Omuro, A; Panageas, KS; Pentsova, EI, 2020) |
| "Perifosine (PRF) is an oral alkylphospholipid with antineoplastic effects and reasonable tolerability." | 6.90 | Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. ( Abrey, LE; DeAngelis, LM; Gavrilovic, IT; Holland, EC; Kaley, TJ; Lassman, AB; Mellinghoff, IK; Nolan, C; Panageas, KS, 2019) |
| "Primary glioblastoma multiforme is the most malignant form of astrocytic tumor with an average survival of approximately 12-14 months." | 5.39 | The short chain cell-permeable ceramide (C6) restores cell apoptosis and perifosine sensitivity in cultured glioblastoma cells. ( Fu, LS; Guo, J; Qin, LS; Sun, G; Xu, J; Yu, ZQ; Zhang, SM; Zhu, J, 2013) |
| "Erucylphosphocholine (ErPC) is a promising antineoplastic drug for the treatment of malignant brain tumors." | 5.32 | MAP kinase pathways involved in glioblastoma response to erucylphosphocholine. ( Eibl, H; Erdlenbruch, B; Jendrossek, V; Kugler, W; Lakomek, M; Otten, K, 2004) |
| "Previous ex vivo spectroscopic data from tissue samples revealed differences in phospholipid metabolites between isocitrate dehydrogenase mutated (IDHmut) and IDH wildtype (IDHwt) gliomas." | 3.91 | In vivo Metabolic Profiles as Determined by ( Bähr, O; Franz, K; Hattingen, E; Pilatus, U; Steinbach, J; Wenger, KJ, 2019) |
| "A series of polymer-drug conjugates based on 2-methacryloyloxyethyl phosphorylcholine (MPC) was prepared with the glioblastoma drug temozolomide (TMZ) as pendent groups." | 3.88 | Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma. ( Emrick, T; Saha, B; Skinner, M; Ward, SM, 2018) |
| "Recent experimental data showed that the PI3K pathway contributes to resistance to temozolomide (TMZ) in paediatric glioblastoma and that this effect is reversed by combination treatment of TMZ with a PI3K inhibitor." | 3.85 | In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells. ( Agliano, A; Al-Saffar, NMS; Balarajah, G; Clarke, PA; Jackson, LE; Jones, C; Leach, MO; Marshall, LV; Pearson, ADJ; Sidhu, J; Workman, P, 2017) |
| "Hexadecylphosphocholine (HePC) or miltefosine based proapoptotic lipid nanovesicles encapsulating paclitaxel for synergistic anticancer effect of paclitaxel and miltefosine in chemoresistant human glioblastoma multiforme (U-87 MG) overexpressing multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp), were developed in this study." | 3.79 | Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy. ( Banerjee, R; Joshi, N; Shanmugam, T; Thakur, A, 2013) |
| "With the aid of the dye JC-1 and cyclosporin A, applied to glioblastoma cells, we now investigated the significance of opening of the mitochondrial permeability transition pore (MPTP) for ErPC3-induced apoptosis in interaction with the TSPO ligands, PK 11195 and Ro5 4864." | 3.74 | Ligands of the mitochondrial 18 kDa translocator protein attenuate apoptosis of human glioblastoma cells exposed to erucylphosphohomocholine. ( Gavish, M; Kugler, W; Lakomek, M; Leschiner, S; Shandalov, Y; Spanier, I; Veenman, L, 2008) |
| "Perifosine was fixed as a 600 mg load on day 1 followed by 100 mg nightly (single agent MTD) until dose level 7 when the load increased to 900 mg." | 2.94 | Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. ( Abrey, LE; DeAngelis, LM; Gavrilovic, I; Holland, EC; Kaley, TJ; Lacouture, ME; Lassman, AB; Ludwig, E; Mellinghoff, IK; Nolan, C; Omuro, A; Panageas, KS; Pentsova, EI, 2020) |
| "Perifosine (PRF) is an oral alkylphospholipid with antineoplastic effects and reasonable tolerability." | 2.90 | Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. ( Abrey, LE; DeAngelis, LM; Gavrilovic, IT; Holland, EC; Kaley, TJ; Lassman, AB; Mellinghoff, IK; Nolan, C; Panageas, KS, 2019) |
| "Many types of cancer, for example glioblastoma, show resistance against current anti-cancer treatments." | 2.50 | Apoptosis induction by erucylphosphohomocholine via the 18 kDa mitochondrial translocator protein: implications for cancer treatment. ( Gavish, M; Kugler, W; Veenman, L, 2014) |
| "Glioblastoma is a highly malignant brain tumor that relentlessly defies therapy." | 2.47 | Genetics of glioblastoma: a window into its imaging and histopathologic variability. ( Belden, CJ; Fadul, CE; Harris, BT; Israel, MA; Pastel, DA; Paulsen, K; Ran, C; Roberts, DW; Valdes, PA, 2011) |
| "High-grade gliomas (WHO grade III anaplastic astrocytoma and grade IV glioblastoma multiforme) are the most common primary tumors in the central nervous system in adults." | 2.45 | High-grade glioma mouse models and their applicability for preclinical testing. ( Beijnen, JH; de Vries, NA; van Tellingen, O, 2009) |
| "Glycine was detected in 24% of all studies, though with a wide range of signal amplitude and extent of the spatial distributions." | 1.40 | Mapping of glycine distributions in gliomas. ( Behari, S; Gupta, RK; Hussain, N; Maudsley, AA; Parra, NA; Roy, B; Sheriff, S; Stoyanova, R, 2014) |
| "Primary glioblastoma multiforme is the most malignant form of astrocytic tumor with an average survival of approximately 12-14 months." | 1.39 | The short chain cell-permeable ceramide (C6) restores cell apoptosis and perifosine sensitivity in cultured glioblastoma cells. ( Fu, LS; Guo, J; Qin, LS; Sun, G; Xu, J; Yu, ZQ; Zhang, SM; Zhu, J, 2013) |
| " Moreover, activity of the survival kinase PKB/Akt was downregulated upon treatment with ErPC/ErPC3 alone or in combination with ionizing radiation." | 1.33 | Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of protein kinase B/Akt-mediated survival-signaling. ( Belka, C; Eibl, H; Faltin, H; Handrick, R; Jendrossek, V; Rübel, A, 2006) |
| "Erucylphosphocholine (ErPC) is a promising antineoplastic drug for the treatment of malignant brain tumors." | 1.32 | MAP kinase pathways involved in glioblastoma response to erucylphosphocholine. ( Eibl, H; Erdlenbruch, B; Jendrossek, V; Kugler, W; Lakomek, M; Otten, K, 2004) |
| "Erucylphosphocholine (ErPC) is a promising candidate for the treatment of human brain tumors." | 1.31 | Structure-activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro. ( Eibl, H; Erdlenbruch, B; Hammersen, K; Jendrossek, V; Krügener, R; Kugler, W; Lakomek, M, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.70) | 18.2507 |
| 2000's | 8 (29.63) | 29.6817 |
| 2010's | 16 (59.26) | 24.3611 |
| 2020's | 2 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Sandbhor, P | 1 |
| Goda, JS | 1 |
| Mohanty, B | 1 |
| Chaudhari, P | 1 |
| Dutt, S | 1 |
| Banerjee, R | 2 |
| Kaley, TJ | 2 |
| Panageas, KS | 2 |
| Pentsova, EI | 1 |
| Mellinghoff, IK | 2 |
| Nolan, C | 2 |
| Gavrilovic, I | 1 |
| DeAngelis, LM | 2 |
| Abrey, LE | 2 |
| Holland, EC | 3 |
| Omuro, A | 1 |
| Lacouture, ME | 1 |
| Ludwig, E | 1 |
| Lassman, AB | 2 |
| Ramezani, S | 1 |
| Vousooghi, N | 1 |
| Ramezani Kapourchali, F | 1 |
| Joghataei, MT | 1 |
| Al-Saffar, NMS | 1 |
| Agliano, A | 1 |
| Marshall, LV | 1 |
| Jackson, LE | 1 |
| Balarajah, G | 1 |
| Sidhu, J | 1 |
| Clarke, PA | 1 |
| Jones, C | 1 |
| Workman, P | 1 |
| Pearson, ADJ | 1 |
| Leach, MO | 1 |
| Wenger, KJ | 1 |
| Hattingen, E | 1 |
| Franz, K | 1 |
| Steinbach, J | 1 |
| Bähr, O | 1 |
| Pilatus, U | 1 |
| Ward, SM | 1 |
| Skinner, M | 1 |
| Saha, B | 1 |
| Emrick, T | 1 |
| Gavrilovic, IT | 1 |
| Qin, LS | 1 |
| Yu, ZQ | 1 |
| Zhang, SM | 1 |
| Sun, G | 1 |
| Zhu, J | 1 |
| Xu, J | 1 |
| Guo, J | 1 |
| Fu, LS | 1 |
| Maudsley, AA | 1 |
| Gupta, RK | 1 |
| Stoyanova, R | 1 |
| Parra, NA | 1 |
| Roy, B | 1 |
| Sheriff, S | 1 |
| Hussain, N | 1 |
| Behari, S | 1 |
| Veenman, L | 3 |
| Gavish, M | 3 |
| Kugler, W | 6 |
| Ríos-Marco, P | 1 |
| Ríos, A | 1 |
| Jiménez-López, JM | 1 |
| Carrasco, MP | 1 |
| Marco, C | 1 |
| Zhang, RR | 1 |
| Swanson, KI | 1 |
| Hall, LT | 1 |
| Weichert, JP | 1 |
| Kuo, JS | 1 |
| Shandalov, Y | 2 |
| Leschiner, S | 1 |
| Spanier, I | 1 |
| Lakomek, M | 5 |
| de Vries, NA | 1 |
| Beijnen, JH | 1 |
| van Tellingen, O | 1 |
| Alten, J | 1 |
| Linnemannstöns, K | 1 |
| Zeno, S | 1 |
| Aki, A | 1 |
| Nair, BG | 1 |
| Morimoto, H | 1 |
| Kumar, DS | 1 |
| Maekawa, T | 1 |
| Pitter, KL | 1 |
| Galbán, CJ | 1 |
| Galbán, S | 1 |
| Tehrani, OS | 1 |
| Saeed-Tehrani, O | 1 |
| Li, F | 1 |
| Charles, N | 1 |
| Bradbury, MS | 1 |
| Becher, OJ | 1 |
| Chenevert, TL | 1 |
| Rehemtulla, A | 1 |
| Ross, BD | 1 |
| Hambardzumyan, D | 1 |
| Belden, CJ | 1 |
| Valdes, PA | 1 |
| Ran, C | 1 |
| Pastel, DA | 1 |
| Harris, BT | 1 |
| Fadul, CE | 1 |
| Israel, MA | 1 |
| Paulsen, K | 1 |
| Roberts, DW | 1 |
| Venkatesh, HS | 1 |
| Chaumeil, MM | 1 |
| Ward, CS | 1 |
| Haas-Kogan, DA | 1 |
| James, CD | 1 |
| Ronen, SM | 1 |
| Thakur, A | 1 |
| Joshi, N | 1 |
| Shanmugam, T | 1 |
| Jendrossek, V | 3 |
| Hammersen, K | 1 |
| Erdlenbruch, B | 3 |
| Krügener, R | 1 |
| Eibl, H | 4 |
| Otten, K | 1 |
| Buchholz, F | 1 |
| Köhler, F | 1 |
| Handrick, R | 1 |
| Rübel, A | 1 |
| Faltin, H | 1 |
| Belka, C | 1 |
| Bhakoo, KK | 1 |
| Williams, SR | 1 |
| Florian, CL | 1 |
| Land, H | 1 |
| Noble, MD | 1 |
| Cheng, LL | 1 |
| Anthony, DC | 1 |
| Comite, AR | 1 |
| Black, PM | 1 |
| Tzika, AA | 1 |
| Gonzalez, RG | 1 |
| Son, BC | 1 |
| Kim, MC | 1 |
| Choi, BG | 1 |
| Kim, EN | 1 |
| Baik, HM | 1 |
| Choe, BY | 1 |
| Naruse, S | 1 |
| Kang, JK | 1 |
3 reviews available for phosphorylcholine and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Apoptosis induction by erucylphosphohomocholine via the 18 kDa mitochondrial translocator protein: implications for cancer treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Membrane; Erucic Acids; Glioblastom | 2014 |
High-grade glioma mouse models and their applicability for preclinical testing.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biomark | 2009 |
Genetics of glioblastoma: a window into its imaging and histopathologic variability.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell S | 2011 |
2 trials available for phosphorylcholine and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Therapy, Combination; Female; Glioblastoma | 2020 |
Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.
Topics: Adult; Aged; Brain Neoplasms; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Ne | 2019 |
22 other studies available for phosphorylcholine and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Bio-polymeric transferrin-targeted temozolomide nanoparticles in gel for synergistic post-surgical GBM therapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Glioblastoma; Glioma; Hydro | 2022 |
Perifosine enhances bevacizumab-induced apoptosis and therapeutic efficacy by targeting PI3K/AKT pathway in a glioblastoma heterotopic model.
Topics: Animals; Apoptosis; Bevacizumab; Caspase 3; Cell Line, Tumor; Gene Expression Regulation, Neoplastic | 2017 |
In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor | 2017 |
In vivo Metabolic Profiles as Determined by
Topics: Adult; Aged; Analysis of Variance; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Diagnosis, Diffe | 2019 |
Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Compoundin | 2018 |
The short chain cell-permeable ceramide (C6) restores cell apoptosis and perifosine sensitivity in cultured glioblastoma cells.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Membrane Permeability; Cell Proliferation; Cell Survival | 2013 |
Mapping of glycine distributions in gliomas.
Topics: Adolescent; Adult; Aged; Astrocytoma; Brain; Brain Mapping; Brain Neoplasms; Choline; Diffusion Magn | 2014 |
Cholesterol homeostasis and autophagic flux in perifosine-treated human hepatoblastoma HepG2 and glioblastoma U-87 MG cell lines.
Topics: Autophagy; Brain Neoplasms; Cell Line, Tumor; Cholesterol; Glioblastoma; Hepatoblastoma; Homeostasis | 2015 |
Diapeutic cancer-targeting alkylphosphocholine analogs may advance management of brain malignancies.
Topics: Antineoplastic Agents; Brain Neoplasms; Disease Management; Glioblastoma; Humans; Multimodal Imaging | 2016 |
Ligands of the mitochondrial 18 kDa translocator protein attenuate apoptosis of human glioblastoma cells exposed to erucylphosphohomocholine.
Topics: Antineoplastic Agents; Apoptosis; Benzodiazepinones; Blotting, Western; Caspases; Cell Line, Tumor; | 2008 |
Potential involvement of F0F1-ATP(synth)ase and reactive oxygen species in apoptosis induction by the antineoplastic agent erucylphosphohomocholine in glioblastoma cell lines : a mechanism for induction of apoptosis via the 18 kDa mitochondrial translocat
Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Butylated Hydroxyanisole; | 2010 |
Label-free determination of the number of biomolecules attached to cells by measurement of the cell's electrophoretic mobility in a microchannel.
Topics: Antibodies; Brain Neoplasms; Cell Biology; Cell Line, Tumor; Dimethylpolysiloxanes; Electrophoresis; | 2010 |
Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; Down-Regulation; D | 2011 |
Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma.
Topics: Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Chromones; Enzyme Inhibitors; Everolimus; Gliob | 2012 |
Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Cell | 2013 |
Structure-activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Division; Cell Survival | 2002 |
MAP kinase pathways involved in glioblastoma response to erucylphosphocholine.
Topics: Brain Neoplasms; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Glioblastoma; Human | 2004 |
Downregulation of Apaf-1 and caspase-3 by RNA interference in human glioma cells: consequences for erucylphosphocholine-induced apoptosis.
Topics: Apoptosis; Apoptotic Protease-Activating Factor 1; BH3 Interacting Domain Death Agonist Protein; Bre | 2005 |
Increased cytotoxicity of ionizing radiation in combination with membrane-targeted apoptosis modulators involves downregulation of protein kinase B/Akt-mediated survival-signaling.
Topics: Apoptosis; Astrocytoma; Caspases; Cell Line, Tumor; Combined Modality Therapy; Down-Regulation; Enzy | 2006 |
Immortalization and transformation are associated with specific alterations in choline metabolism.
Topics: Animals; Antigens, Viral, Tumor; Cell Division; Cell Line, Transformed; Choline; Glioblastoma; Human | 1996 |
Quantification of microheterogeneity in glioblastoma multiforme with ex vivo high-resolution magic-angle spinning (HRMAS) proton magnetic resonance spectroscopy.
Topics: Adult; Biopsy; Brain Neoplasms; Choline; Glioblastoma; Gliosis; Humans; Lactates; Lipids; Magnetic R | 2000 |
Proton magnetic resonance chemical shift imaging (1H CSI)-directed stereotactic biopsy.
Topics: Adult; Aspartic Acid; Biopsy, Needle; Brain; Brain Neoplasms; Creatine; Diagnosis, Differential; Ene | 2001 |